Citations

Showing 10 of 108094 citations.

Performance of current risk stratification models for predicting mortality in patients with heart failure: a systematic review and meta-analysis
Siddiqi, Tariq Jamal , Ahmed, Aymen , Greene, Stephen J. , Oshunbade, Adebamike , Hall, Michael E. , Jain, Vardhmaan , Khan, Muhammad Shahzeb , Murad, Mohammad Hassan, Shahid, Izza , Usman, Muhammad , Alkhouli, Mohamad , Murad, M. Hassan , Khera, Rohan , Spall, Harriette G.C. Van

Mayo Clinic

European Journal of Preventive Cardiology | August 3, 2022 | Volume: 29 | Issue: 15 | Pages: 2027-2048

10.1093/eurjpc/zwac148 | PMID 35919956 Get It

Abstract Aims There are several risk scores designed to predict mortality in patients with heart failure (HF). This study aimed to assess performance of risk scores validated for mortality prediction in patients with acute HF (AHF) and chronic HF. Methods and results MEDLINE and Scopus were searched from January 2015 to January 2021 for studies which internally or externally validated risk models for predicting all-cause mortality in patients with AHF and chronic HF. Discrimination data were analysed using C-statistics, and pooled using generic inverse-variance random-effects model. Nineteen studies (n = 494 156 patients; AHF: 24 762; chronic HF mid-term mortality: 62 000; chronic HF long-term mortality: 452 097) and 11 risk scores were included. Overall, discrimination of risk scores was good across the three subgroups: AHF mortality [C-statistic: 0.76 (0.68–0.83)], chronic HF mid-term mortality [1 year; C-statistic: 0.74 (0.68–0.79)], and chronic HF long-term mortality [≥2 years; C-statistic: 0.71 (0.69–0.73)]. MEESSI-AHF [C-statistic: 0.81 (0.80–0.83)] and MARKER-HF [C-statistic: 0.85 (0.80–0.89)] had an excellent discrimination for AHF and chronic HF mid-term mortality, respectively, whereas MECKI had good discrimination [C-statistic: 0.78 (0.73–0.83)] for chronic HF long-term mortality relative to other models. Overall, risk scores predicting short-term mortality in patients with AHF did not have evidence of poor calibration (Hosmer–Lemeshow P > 0.05). However, risk models predicting mid-term and long-term mortality in patients with chronic HF varied in calibration performance. Conclusions The majority of recently validated risk scores showed good discrimination for mortality in patients with HF. MEESSI-AHF demonstrated excellent discrimination in patients with AHF, and MARKER-HF and MECKI displayed an excellent discrimination in patients with chronic HF. However, modest reporting of calibration and lack of head-to-head comparisons in same populations warrant future studies.
Assessment and Optimization of Explainable Machine Learning Models Applied to Transcriptomic Data
Zhao, Yongbing , Shao, Jinfeng , Asmann, Yan W. , Asmann, Yan W

Mayo Clinic

Genomics, Proteomics & Bioinformatics | August 3, 2022 | Volume: 20 | Issue: 5 | Pages: 899-911

10.1016/j.gpb.2022.07.003 | PMID 35931322 Get It

Abstract Explainable artificial intelligence aims to interpret how machine learning models make decisions, and many model explainers have been developed in the computer vision field. However, understanding of the applicability of these model explainers to biological data is still lacking. In this study, we comprehensively evaluated multiple explainers by interpreting pre-trained models for predicting tissue types from transcriptomic data and by identifying the top contributing genes from each sample with the greatest impacts on model prediction. To improve the reproducibility and interpretability of results generated by model explainers, we proposed a series of optimization strategies for each explainer on two different model architectures of multilayer perceptron (MLP) and convolutional neural network (CNN). We observed three groups of explainer and model architecture combinations with high reproducibility. Group II, which contains three model explainers on aggregated MLP models, identified top contributing genes in different tissues that exhibited tissue-specific manifestation and were potential cancer biomarkers. In summary, our work provides novel insights and guidance for exploring biological mechanisms using explainable machine learning models.
Diabetic Ketoacidosis in Pregnancy: Clinical Risk Factors, Presentation, and Outcomes
Dhanasekaran, Maheswaran , Mohan, Sneha , Erickson, Dana , Shah, Pankaj, Szymanski, Linda M. , Szymanski, Linda, Adrian, Vella, Egan, Aoife M. , Vella, Adrian

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | August 2, 2022 | Volume: 107 | Issue: 11 | Pages: 3137-3143

10.1210/clinem/dgac464 | PMID 35917830 Get It

Abstract Context Diabetic ketoacidosis (DKA) in pregnancy is an obstetric emergency with risk of maternofetal death. Objective This work aimed to evaluate DKA events in pregnant women admitted to our inpatient obstetric service, and to examine associated clinical risk factors, presentation, and pregnancy outcomes. Methods A retrospective cohort study was conducted at the Mayo Clinic, Rochester, Minnesota, USA, and included women aged 17 to 45 years who were treated for DKA during pregnancy between January 1, 2004 and December 31, 2021. Main outcome measures included maternal and fetal death along with a broad spectrum of maternal and fetal pregnancy outcomes. Results A total of 71 DKA events were identified in 58 pregnancies among 51 women, 48 (82.8%) of whom had type 1 diabetes. There were no maternal deaths, but fetal demise occurred in 10 (17.2%) pregnancies (6 miscarriages and 4 stillbirths). Maternal social stressors were frequently present (n = 30, 51.0%), and glycemic control was suboptimal (median first trimester glycated hemoglobin A1c = 9.0%). Preeclampsia was diagnosed in 17 (29.3%) pregnancies. Infants born to women with DKA were large for gestational age (n = 16, 33.3%), suffered from neonatal hypoglycemia (n = 29, 60.4%) and required intensive care unit admission (n = 25, 52.1%). Conclusion DKA is associated with a high rate of maternofetal morbidity and fetal loss. Prenatal education strategies for women with diabetes mellitus should include a strong focus on DKA prevention, and clinicians and patients should have a high index of suspicion for DKA in all pregnant women who present with symptoms that could be attributed to this condition.
Assessment of Electronic Health Record for Cancer Research and Patient Care Through a Scoping Review of Cancer Natural Language Processing
Wang, Liwei , Fu, Sunyang , Wen, Andrew , Ruan, Xiaoyang , Liu, Sijia , Moon, Sungrim , Mai, Michelle , Riaz, Irbaz Bin , Wang, Nan , Xu, Hua , He, Huan , Liu, Sijia , Moon, Sungrim , Riaz, Irbaz B , Yang, Ping , Warner, Jeremy L , Liu, Hongfang , Fu, Sunyang , Wen, Andrew , He, Huan , Yang, Ping , Warner, Jeremy L. , Liu, Hongfang

Mayo Clinic

JCO Clinical Cancer Informatics | August 2, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/cci.22.00006 | PMID 35917480 Get It

PURPOSEThe advancement of natural language processing (NLP) has promoted the use of detailed textual data in electronic health records (EHRs) to support cancer research and to facilitate patient care. In this review, we aim to assess EHR for cancer research and patient care by using the Minimal Common Oncology Data Elements (mCODE), which is a community-driven effort to define a minimal set of data elements for cancer research and practice. Specifically, we aim to assess the alignment of NLP-extracted data elements with mCODE and review existing NLP methodologies for extracting said data elements.METHODSPublished literature studies were searched to retrieve cancer-related NLP articles that were written in English and published between January 2010 and September 2020 from main literature databases. After the retrieval, articles with EHRs as the data source were manually identified. A charting form was developed for relevant study analysis and used to categorize data including four main topics: metadata, EHR data and targeted cancer types, NLP methodology, and oncology data elements and standards.RESULTSA total of 123 publications were selected finally and included in our analysis. We found that cancer research and patient care require some data elements beyond mCODE as expected. Transparency and reproductivity are not sufficient in NLP methods, and inconsistency in NLP evaluation exists.CONCLUSIONWe conducted a comprehensive review of cancer NLP for research and patient care using EHRs data. Issues and barriers for wide adoption of cancer NLP were identified and discussed.
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
Babiker, Hani M. , Subbiah, Vivek , Agarwala, Sanjiv S. , Algazi, Alain P. , Schachter, Jacob , Lotem, Michael, Maurice‐Dror, Corinne , Hendler, Daniel , Rahimian, Shah, Minderman, Hans , Mahadevan, Daruka , Bernatchez, Chantale , Hultsch, Rolf, Kaplan, Nadia, Woodhead, Gregory , Hennemeyer, Charles , Chunduru, Srinivas K., Anderson, Peter M. , Diab, Adi , Babiker, Hani , Borazanci, Erkut , Subbiah, Vivek , Agarwala, Sanjiv , Algazi, Alain , Schachter, Jacob , Maurice-Dror, Corinne , Hendler, Daniel , Haymaker, Cara , Bernatchez, Chantale , Kaplan, Nadia , Woodhead, Gregory , Hennemeyer, Charles , Puzanov, Igor , Borazanci, Erkut , Haymaker, Cara , Murthy, Ravi , Puzanov, Igor

Mayo Clinic

Clinical Cancer Research | August 2, 2022 | Volume: 28 | Issue: 23 | Pages: 5079-5087

10.1158/1078-0432.ccr-21-4486 | PMID 35917516 Get It

Abstract Purpose: Tilsotolimod is an investigational synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models. The ILLUMINATE-101 phase I study explored the safety, dose, efficacy, and immune effects of intratumoral (it) tilsotolimod monotherapy in multiple solid tumors. Patients and Methods: Patients with a diagnosis of refractory cancer not amenable to curative therapies received tilsotolimod in doses escalating from 8 to 32 mg into a single lesion at weeks 1, 2, 3, 5, 8, and 11. Additional patients with advanced malignant melanoma were enrolled into an expansion cohort at the 8 mg dose. Objectives included characterizing the safety, establishing the dose, efficacy, and immunologic assessment. Blood samples and tumor biopsies of injected and noninjected lesions were obtained at baseline and 24 hours after treatment for immune analyses. Results: Thirty-eight and 16 patients were enrolled into the dose escalation and melanoma expansion cohorts, respectively. Deep visceral injections were conducted in 91% of patients. No dose-limiting toxicities (DLT) or grade 4 treatment-related adverse events were observed. Biopsies 24 hours after treatment demonstrated an increased IFN pathway signature and dendritic cell maturation. Immunologic profiling revealed upregulation of IFN-signaling genes and modulation of genes for checkpoint proteins. In the dose escalation cohort, 12 (34%) of 35 evaluable patients achieved a best overall response rate (ORR) of stable disease (SD), whereas 3 (19%) of 16 evaluable patients in the melanoma cohort achieved stable disease. Conclusions: Overall, tilsotolimod monotherapy was generally well tolerated and induced rapid, robust alterations in the tumor microenvironment. See related commentary by Punekar and Weber, p. 5007
Surgical Pathology of Diffuse Parenchymal Lung Disease in Patients With Psoriasis or Psoriatic Arthritis
Butt, Yasmeen M. , Tazelaar, Henry D. , Roden, Anja C. , Larsen, Brandon T. , Smith, Maxwell L. , Tazelaar, Henry D. , Mengoli, Maria Cecilia

Mayo Clinic

Archives of Pathology & Laboratory Medicine | August 2, 2022 | Volume: 147 | Issue: 5 | Pages: 525-533

10.5858/arpa.2021-0616-oa | PMID 35917487 Get It

Context.— Diffuse parenchymal lung disease (DPLD) is a well-recognized complication of systemic connective tissue disease (CTD) but rarely arises in patients with psoriasis or psoriatic arthritis, a poorly understood phenomenon. Objective.— To characterize DPLD associated with psoriasis or psoriatic arthritis, with or without prior immunomodulation. Design.— Pathology consultation files were searched for patients having psoriasis or psoriatic arthritis and DPLD. After excluding cases with active infection or smoking-related DPLD only, 44 patients (22 women; median age, 60 years; range, 23–81 years) were enrolled. Clinical history and pathology slides were reviewed. Results.— Twenty-seven of 44 patients (61%) had psoriatic arthritis; the remainder had psoriasis alone. Most presented many years later with nonspecific respiratory symptoms. Nearly one-third had no prior immunosuppression, and most had no concomitant CTD. Radiographically, ground-glass opacities, consolidation, and/or reticulation were typical. Histologically, nonspecific interstitial pneumonia and unclassifiable fibrosis were seen in 24 patients (55%) and 8 patients (18%), respectively; usual interstitial pneumonia and airway-centered fibrosis were rare. Superimposed acute lung injury was common, usually manifesting as organizing pneumonia. Lymphoplasmacytic infiltrates, lymphoid aggregates, and chronic pleuritis were frequent. Interstitial granulomas were seen in 17 patients (39%) but were usually rare, poorly formed, and nonnecrotizing. No histologic differences were apparent among patients with or without concomitant CTDs or prior therapy. Conclusions.— Some patients with psoriasis or psoriatic arthritis develop clinically significant DPLD, even without prior therapy. Histopathologic findings mirror changes seen with other CTDs. Additional studies are warranted to clarify the association between psoriasis or psoriatic arthritis and DPLD.
Review 1: "Antibody Response to SARS-CoV-2 mRNA Vaccine in Lung Cancer Patients: Reactivity to Vaccine Antigen and Variants of Concern"
Mangat, Chetna

Mayo Clinic

No container title available | August 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1162/2e3983f5.03e16a51 Get It

Reviews of "Antibody Response to SARS-CoV-2 mRNA Vaccine in Lung Cancer Patients: Reactivity to Vaccine Antigen and Variants of Concern"
Mangat, Chetna

Mayo Clinic

No container title available | August 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1162/2e3983f5.f599f969 Get It

7-T Neuromelanin and R2* MRI in Parkinson Disease
Lakhani, Dhairya A. , Middlebrooks, Erik H. , Middlebrooks, Erik H , Lakhani, Dhairya

Mayo Clinic

Radiology | August 2, 2022 | Volume: 305 | Issue: 2 | Pages: 296-296

10.1148/radiol.220230 | PMID 35916676 Get It